Latest Roche Stories
SAN DIEGO, Nov. 5, 2010 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc.
SAN DIEGO, Oct. 11 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc.
NUTLEY, N.J. and BASEL, Switzerland Oct. 4 /PRNewswire/ -- Roche announced today that Jacques Banchereau, Ph.D., has joined Roche as Senior Vice President and Head of the Inflammation and Virology Discovery and Translational Areas (DTAs).
NUTLEY, N.J., Sept.
IPSWICH, Mass., Aug. 4 /PRNewswire/ -- New England Biolabs is pleased to announce that Canada's Michael Smith Genome Sciences Center has selected New England Biolabs as one of its key suppliers for next-generation sequencing library construction reagents.
NUTLEY, N.J., July 26 /PRNewswire/ -- Roche announced today that Karen Lackey has been named Vice President and Head of Medicinal Chemistry, effective immediately.
Federal health scientists said Friday that follow-up studies of a Roche breast cancer drug showed it failed to slow tumor growth or extend patient lives.
IPSWICH, Mass., July 13 /PRNewswire/ -- New England Biolabs (NEB) has expanded its line of reagents for sample preparation with the introduction of NEBNext(TM) Quick DNA Sample Prep Reagent Set 2 and Master Mix Set 2, both suitable for library construction for Roche's 454 GS FLX Titanium(TM) and GS Junior(TM) instruments.
WALTHAM, Mass., July 1 /PRNewswire/ -- X-Chem, Inc. today announced the signing of a multi-year collaborative agreement with Roche to apply X-Chem's proprietary platform to the rapid discovery of drug candidates against several of Roche's high-value therapeutic targets.
YORKTOWN HEIGHTS, N.Y. and BRANFORD, Conn., July 1 /PRNewswire-FirstCall/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and IBM (NYSE: IBM) announced today an agreement to develop a nanopore-based technology that will directly read and sequence human DNA quickly and efficiently.
- An imitative word; an onomatopoetic word.